UK: Changes to amendment submission to HRA/MREC

2024-02-29T15:14:45+00:00July 8th, 2020|Categories: Clinical Trial, Europe, UK|Tags: , , |

On 2 June 2020 changes were introduced in the Integrated Research Application System (IRAS) to the way amendments are notified to Research Ethics Committees and NHS/HSC in the UK: Project-based research should now prepare amendments using the Amendment Tool. Amendments [...]

EMA: Points to consider on implications of COVID-19 on methodological aspects of ongoing clinical trials

2024-02-02T11:53:30+00:00July 2nd, 2020|Categories: Clinical Trial, Covid-19, Europe|Tags: , , |

The European Medicine Agency (EMA) released a guidance to illustrate some points to consider on implications of COVID-19 on methodological aspects of ongoing clinical trials. "At this point in time it is not possible to provide general advice on [...]

Czech Republic: Opinion of the SÚKL Department of Clinical Trials on ongoing clinical trials and on clinical trials not yet initiated in relation to COVID-19

2024-02-02T10:24:34+00:00June 30th, 2020|Categories: Clinical Trial, Covid-19, Eastern Europe, Europe, Regulatory|Tags: , , , |

The Czech Authority State Institute for Drug Control (SÚKL) updated its general recommendations respecting the current epidemiological situation with coronavirus regarding ongoing or not yet started clinical trials and the release of emergency measures of the government. This opinion [...]

US: FDA published finalized guidance on inspections of medical device establishments

2024-02-29T17:02:19+00:00June 29th, 2020|Categories: Clinical Trial, Compliance, Regulatory, USA|Tags: , , , |

The Food and Drug Administration (FDA) issued guidance on inspections of medical device establishments. The finalized document follows draft guidance issued on March 28, 2019, filling a requirement of the FDA Reauthorization Act of 2017 (FDARA). The guidance specifies [...]

US: FDA published Q&A guidance on the effects of the COVID-19 emergency on formal meetings and user fee applications for medical devices

2024-02-29T17:05:07+00:00June 24th, 2020|Categories: Clinical Trial, Covid-19, Regulatory, USA|Tags: , , , , |

FDA published a Q&A document to respond frequently asked questions from submitters and applicants on regulatory matters and issues relating to medical devices arising from  the COVID-19 public health emergency. This guidance addresses the following: Meetings with Industry MDUFA [...]

FDA provides statistical guidance for trials during COVID-19

2024-02-26T09:26:25+00:00June 18th, 2020|Categories: Clinical Trial, Compliance, Covid-19, USA|Tags: , , , |

The FDA issued guidance to provide sponsors with statistical advice in order to maintain trial integrity and reduce the impact of the COVID-19 emergency on clinical trials conduct. This new document follows the agency’s guidances on the conduct of [...]

Spain: Monitoring visits in hospitals allowed again

2024-02-29T14:18:56+00:00June 8th, 2020|Categories: Clinical Trial, Covid-19, Europe, Western Europe|Tags: , , |

Good news from Spain! Our monitors informed us about the restart of onsite monitoring visits as of today June 8th, 2020 after the break imposed by the COVID-19 emergency. Meditrial is closely monitoring the situation in all countries to restart [...]

UK: The MHRA provides regulatory flexibilities resulting from COVID-19

2024-02-29T16:31:53+00:00June 8th, 2020|Categories: Clinical Trial, Covid-19, Europe, UK|Tags: , , , |

The MHRA updated its Guidance for industry on flexible approaches to regulation they are taking during the COVID-19 outbreak. In the last update from 5th June 2020, the Agency added information on audits of Notified Bodies and manufacturers in [...]

USA: FDA updates its guidance on the conduct of clinical trials of medical products during COVID-19 emergency

2024-02-29T17:18:32+00:00June 5th, 2020|Categories: Clinical Trial, Covid-19, USA|Tags: , , , |

The US Food and Drug Administration (FDA) updates its guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. The Agency added information about electronic signatures for informed consent and provided clarification about remote assessments during [...]

UK: MHRA launched Yellow Card website for reporting COVID-19 related issues

2024-02-29T15:25:55+00:00June 3rd, 2020|Categories: Clinical Trial, Covid-19, UK|Tags: , , |

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) launched Yellow Card, a dedicated site for reporting COVID-19 related adverse medical device incidents and side effects from medicines. You can report on Yellow Card if: a medicine causes side [...]

Go to Top